What Proportion of Vancomycin Trough Levels Are Drawn Too Early? Frequency and Impact on Clinical Actions

被引:45
|
作者
Morrison, Aileen P. [1 ,2 ]
Melanson, Stacy E. F. [1 ]
Carty, Marcy G. [2 ]
Bates, David W. [2 ]
Szumita, Paul M. [3 ]
Tanasijevic, Milenko J. [1 ]
机构
[1] Harvard Univ, Dept Pathol, Div Clin Labs, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pharm Serv, Boston, MA 02115 USA
关键词
Vancomycin; Therapeutic drug monitoring; Specimen collection; Quality; Patient safety; APPROPRIATENESS; SYSTEM;
D O I
10.1309/AJCPDSYS0DVLKFOH
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vancomycin trough levels are recommended to predict vancomycin efficacy, and inaccurate levels may lead to inappropriate clinical actions. However, the frequency of timing errors and associated clinical impact is unknown. We retrospectively analyzed vancomycin levels (n = 2,597) measured during 13 months at a large academic medical center. Of the specimens, 41.3% were drawn too early. These samples yielded significantly higher average SD vancomycin concentrations than correctly timed samples (22.1 +/- 11.7 mg/L vs 15.5 mg/L +/- 8.6 mg/L; P < .001), and, consequently, clinicians were more likely to decrease, discontinue, or hold a patient's vancomycin dose (25.6% vs 21.4%; P < .02) or repeat the vancomycin level (29.2% vs 20.0%; P < .001). A substantial proportion of specimens collected to assess vancomycin efficacy were drawn too early, leading to overestimation of patients' true trough level and possible underdosing of vancomycin or a high rate of repeat tests far vancomycin.
引用
收藏
页码:472 / 478
页数:7
相关论文
共 37 条
  • [1] IMPACT OF HIGHER TARGET VANCOMYCIN TROUGH LEVELS ON INCIDENCE OF VANCOMYCIN-INDUCED AKI
    Bulloch, Marilyn
    Paumen, Lyndsi
    Eure, Stephen
    Stewart, Joseph
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [2] Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis
    Zonozi, Reza
    Wu, Aozhou
    Shin, Jung-Im
    Secora, Alex
    Coresh, Josef
    Inker, Lesley A.
    Chang, Alex R.
    Grams, Morgan E.
    MAYO CLINIC PROCEEDINGS, 2019, 94 (01) : 17 - 26
  • [3] Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients
    Chuma, Masayuki
    Makishima, Makoto
    Imai, Toru
    Tochikura, Naohiro
    Suzuki, Shinichiro
    Kuwana, Tsukasa
    Sawada, Nami
    Komatsu, Tomohide
    Sakaue, Takako
    Kikuchi, Norikazu
    Yoshida, Yoshikazu
    Kinoshita, Kosaku
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 109 - 114
  • [4] Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort
    Kullar, Ravina
    Davis, Susan L.
    Taylor, Thomas N.
    Kaye, Keith S.
    Rybak, Michael J.
    PHARMACOTHERAPY, 2012, 32 (03): : 195 - 201
  • [5] Impact of Ustekinumab Trough Levels on Clinical Outcomes in Patients With Inflammatory Bowel Disease
    Nolan, Lindsey
    Meadors, Crystal
    Mcpheeters, Chelsey
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S18 - S19
  • [6] Impact of Serum Vancomycin Trough Levels in the Treatment of Central Nervous System Shunt Infections Caused by Coagulase-Negative Staphylococci
    Gibson, Ashley
    Kaplan, Sheldon L.
    Vallejo, Jesus G.
    PEDIATRIC NEUROSURGERY, 2018, 53 (04) : 243 - 246
  • [7] Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children
    Yoo, Ree Nar
    Kim, Seo Hee
    Lee, Jina
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2017, 32 (01) : 22 - 28
  • [8] Impact of Early Posttransplant Calcineurin Inhibitors (CNI) Trough Levels On Long-Term Outcome
    Di Maira, Tommaso
    Rubin, Angel
    Aguilera, Victoria
    San Juan, Fernando
    Vinaixa, Carmen
    Montalva, Eva
    Moya, Angel
    Lopez, Rafael
    Belloch, Salvador
    Prieto, Martin
    Berenguer, Marina
    TRANSPLANTATION, 2015, 99 : 275 - 275
  • [9] INFLIXIMAB TROUGH LEVELS AND DISEASE ACTIVITY PREDICT EARLY CLINICAL RESPONSE IN PATIENTS WITH AXIAL SPONDYLOARHTRITIS
    Martinez-Feito, Ana
    Plasencia, Chamaida
    Hernandez-Breijo, Borja
    Navarro-Compan, Victoria
    Peiteado, Diana
    Villalva, Alejandro
    Nuno, Laura
    Monjo, Irene
    Diego, Cristina
    Pascual-Salcedo, Dora
    Balsa, Alejandro
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 885 - 885
  • [10] Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kurent, Tina
    Kozelj, Matic
    Novak, Gregor
    Compernolle, Griet
    Tops, Sophie
    Gils, Ann
    Drobne, David
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 741 - 749